Skip to the answer

Abiraterone

Abiraterone is an oral prostate cancer medicine, taken with a steroid, that lowers the hormones (androgens) that fuel the cancer. It is used for metastatic castration-resistant prostate cancer and, in some products, metastatic high-risk castration-sensitive prostate cancer.

Brand names ZytigaYonsaAbirtega
Drug class Cytochrome P450 17a1 Inhibitor
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 31 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Abiraterone at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Abiraterone, on the market since about 2010 and available as a generic, is a well-established tablet for prostate cancer that has spread, added to hormone-lowering treatment and taken with a steroid, and it blocks an enzyme (CYP17) that the testes, adrenal glands and the tumor itself use to make androgens, the male hormones that feed the cancer. Most people tolerate it reasonably well, and tiredness, hot flushes, joint aches and ankle swelling are what they notice most. The thing to watch is your liver, so call promptly about yellow skin or eyes, dark urine or severe belly pain, and keep up the frequent liver, blood pressure and potassium checks.

Clinical pearls

  • Food greatly boosts absorption, so take Zytiga, Abirtega or generic tablets with no food 2 hours before or 1 hour after.
  • Never skip or stop your steroid on your own, and ask about extra steroid during serious illness or major stress.
  • If you take pioglitazone or repaglinide for diabetes, check your blood sugar more often, since severe lows have occurred.
  • Pregnant women should not handle the tablets, and men need effective contraception until 3 weeks after the last dose.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet
Earliest FDA record2010
Companies listing it with the FDA23
FDA label last updatedFeb 26, 2025
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Abiraterone, written from its FDA label.

What Abiraterone is used for

▾

Abiraterone is used with a steroid to treat prostate cancer that has spread.

  • Abiraterone acetate tablets, Abirtega and Zytiga (with prednisone): metastatic castration-resistant prostate cancer (CRPC).
  • Abiraterone acetate tablets, Abirtega and Zytiga (with prednisone): metastatic high-risk castration-sensitive prostate cancer (CSPC).
  • Yonsa (with methylprednisolone): metastatic CRPC only.

How Abiraterone works

▾

Abiraterone is turned into its active form in the body. It blocks CYP17, an enzyme needed to make androgens (hormones such as testosterone) in the testes, adrenal glands and prostate tumor tissue. Prostate cancer that depends on androgens responds when those levels drop.

Other hormone therapies, like GnRH agonists or orchiectomy, only reduce androgen production in the testes. Abiraterone also reduces androgens from the adrenals and tumor. Blocking CYP17 can raise mineralocorticoid hormones, which is why a steroid is taken with it.

Abiraterone dosage

▾

Abiraterone is a tablet taken by mouth once daily, together with a steroid. You also need a GnRH analog or prior orchiectomy.

  • Abiraterone acetate tablets, Abirtega and Zytiga: take on an empty stomach, with no food 2 hours before and 1 hour after.
  • Yonsa: take with or without food. Its dosing differs from other abiraterone products.
  • Swallow tablets whole with water, and do not crush or chew.

Follow your prescriber and label for your exact dose and what to do if you miss one.

Dosing details from the FDA-approved label

From the Abiraterone prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Metastatic castration-resistant prostate cancer (CRPC)
    • 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily
    • Take as a single dose once daily on an empty stomach; do not eat food 2 hours before and 1 hour after; swallow whole with water; do not crush or chew. Patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
  • Metastatic high-risk castration-sensitive prostate cancer (CSPC)
    • 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally once daily
    • Take as a single dose once daily on an empty stomach; do not eat food 2 hours before and 1 hour after; swallow whole with water. Patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
  • Baseline moderate hepatic impairment (Child-Pugh Class B)
    • 250 mg once daily
    • Monitor ALT, AST and bilirubin before treatment, every week for the first month, every two weeks for the following two months, and monthly thereafter. Discontinue and do not re-treat if ALT/AST greater than 5 x ULN or total bilirubin greater than 3 x ULN.
  • Baseline severe hepatic impairment (Child-Pugh Class C)
    • Do not use abiraterone acetate tablets
  • Hepatotoxicity during treatment (ALT and/or AST greater than 5 x ULN or total bilirubin greater than 3 x ULN)
    • Interrupt treatment
    • May restart at a reduced dose of 750 mg once daily after liver tests return to baseline or to AST and ALT less than or equal to 2.5 x ULN and total bilirubin less than or equal to 1.5 x ULN. If hepatotoxicity recurs, may restart at 500 mg once daily after the same recovery
    • If it recurs at 500 mg once daily, discontinue
    • Monitor transaminases and bilirubin at least every two weeks for three months and monthly thereafter. Permanently discontinue if ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN occur concurrently without biliary obstruction or other cause.
  • Concomitant strong CYP3A4 inducer that must be co-administered
    • Increase dosing frequency to twice a day only during the co-administration period (e.g., from 1,000 mg once daily to 1,000 mg twice a day)
    • Reduce back to the previous dose and frequency if the inducer is discontinued.
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Metastatic castration-resistant prostate cancer: • Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally twice daily. ( 2.1 ) Metastatic castration-sensitive prostate cancer: • Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally once daily. ( 2.2 ) Patients receiving abiraterone acetate tablets should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone acetate tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking abiraterone acetate tablets. The tablets must be swallowed whole with water. Do not crush or chew tablets. ( 2.3 ) Dose Modification: • For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the abiraterone acetate tablets starting dose to 250 mg once daily. ( 2.4 ) • For patients who develop hepatotoxicity during treatment, hold abiraterone acetate tablets until recovery. Retreatment may be initiated at a reduced dose. Abiraterone acetate tablets should be discontinued if patients develop severe hepatotoxicity. ( 2.4 ) 2.1 Recommended Dose for Metastatic CRPC The recommended dose of abiraterone acetate tablets is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily. 2.2 Recommended Dose for Metastatic High-Risk CSPC The recommended dose of abiraterone acetate tablets is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg administered orally once daily. 2.3 Important Administration Instructions Patients receiving abiraterone acetate tablets should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone acetate tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking abiraterone acetate tablets. The tablets must be swallowed whole with water. Do not crush or chew tablets . 2.4 Dose Modification Guidelines in Hepatic Impairment and Hepatotoxicity Hepatic Impairment In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of abiraterone acetate tablets to 250 mg once daily.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Abiraterone side effects

▾

Common side effects include:

Common side effects

  • Tiredness (fatigue)
  • Joint pain or swelling
  • High blood pressure
  • Nausea, vomiting or diarrhea
  • Swelling from fluid retention (edema)
  • Low potassium
  • Hot flushes
  • Cough, upper respiratory infection or headache

When to get medical help

  • Call your doctor right away if you have signs of liver problems, such as yellowing of the skin or eyes, dark urine, or severe nausea or belly pain. Liver injury can be severe and even fatal.
  • Get help for signs of low potassium, high blood pressure or fluid retention, such as muscle weakness, heart palpitations, new swelling or shortness of breath.
  • Tell your doctor if you feel very weak, dizzy or faint, or become very ill. Adrenal insufficiency (the body not making enough steroid hormones) can occur, especially if you miss or stop your steroid, or during an infection or stress.
  • Seek help for heart rhythm problems or heart failure symptoms. Rhythm changes, including QT prolongation and Torsades de Pointes, have been reported in people who develop low potassium.
  • Report symptoms of low blood sugar if you have diabetes. Severe cases have occurred in people also taking pioglitazone or repaglinide.

Blood tests may also show anemia, high cholesterol or triglycerides, high blood sugar, or high liver enzymes. Call your doctor promptly about liver problems, heart symptoms, severe weakness or dizziness, or low blood sugar.

Abiraterone warnings and precautions

▾
  • Liver toxicity: can be severe and fatal. It most often shows up in the first 3 months, so frequent blood tests are needed.
  • Mineralocorticoid excess: can cause high blood pressure, low potassium and fluid retention. This is a particular concern with heart failure, a recent heart attack or rhythm problems.
  • Adrenal insufficiency: a risk if the steroid is missed, reduced or stopped, or with infection or stress.
  • Radium Ra 223 dichloride: combining it with abiraterone plus prednisone raised fractures and deaths in a trial and is not recommended.
  • Embryo-fetal harm: it can harm an unborn baby.
  • Low blood sugar: severe cases were reported with pioglitazone or repaglinide.

Abiraterone interactions

▾

Some medicines change how abiraterone works, or how it changes other drugs.

  • Strong CYP3A4 inducers (such as rifampin): can cut abiraterone levels by about 55%, so avoid them if possible.
  • CYP2D6 drugs with a narrow safety margin (such as thioridazine): abiraterone raises their levels, so avoid them or lower their dose.
  • Pioglitazone: levels rose about 46%, and low blood sugar can occur, so watch closely.
  • Repaglinide: low blood sugar risk, so monitor glucose.
  • Radium Ra 223 dichloride: not recommended together.
  • Food: greatly increases absorption, so follow the fasting directions for your product.

Interactions listed in the FDA-approved label

From the Abiraterone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant use; if one must be co-administered, increase the abiraterone acetate dosing frequency to twice a day only during co-administration.
  • Strong CYP3A4 inhibitors (ketoconazole): Ketoconazole had no clinically meaningful effect on the pharmacokinetics of abiraterone.
  • CYP2D6 substrates (e.g., thioridazine, dextromethorphan): Abiraterone inhibits CYP2D6; dextromethorphan Cmax and AUC were increased 2.8- and 2.9-fold. Avoid co-administration with CYP2D6 substrates with a narrow therapeutic index; if an alternative cannot be used, consider a dose reduction of the substrate.
  • CYP2C8 substrates (pioglitazone): Abiraterone inhibits CYP2C8; the AUC of pioglitazone was increased by 46%. Monitor closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index.
  • CYP1A2 substrates (theophylline): No increase in systemic exposure of theophylline was observed.
Read the label’s full interactions text

7 DRUG INTERACTIONS • CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during abiraterone acetate tablets treatment. If a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate tablets dosing frequency. ( 2.5 , 7.1 ) • CYP2D6 Substrates: Avoid co-administration of abiraterone acetate tablets with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate. ( 7.2 ) 7.1 Drugs that Inhibit or Induce CYP3A4 Enzymes Based on in vitro data, abiraterone acetate tablets are a substrate of CYP3A4. In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during abiraterone acetate tablets treatment. If a strong CYP3A4 inducer must be co-administered, increase the abiraterone acetate tablets dosing frequency [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ] . In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Clinical Pharmacology (12.3) ] . 7.2 Effects of Abiraterone on Drug Metabolizing Enzymes Abiraterone acetate tablets are an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the C max and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug [see Clinical Pharmacology (12.3) ] .

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿181 supplements and herbs with documented Abiraterone interactions, ranked by severity Check Abiraterone against a supplement or herb →

Before taking Abiraterone

▾
  • Severe liver impairment (Child-Pugh Class C): do not use. Moderate impairment calls for a lower starting dose.
  • Heart disease, heart failure, recent heart attack, rhythm problems, high blood pressure or low potassium: need control and close monitoring.
  • Diabetes: blood sugar should be monitored, especially with pioglitazone or repaglinide.
  • Pregnancy: it can cause fetal harm. Men with partners who could become pregnant should use effective contraception during treatment and for 3 weeks after. Women who are or may become pregnant should not handle the tablets.
  • Breastfeeding: no information is available, and safety in females has not been established.
  • Fertility: it may impair fertility in men.
  • Children: safety and effectiveness have not been established.
  • Older adults: no overall differences were seen, though some may be more sensitive.
  • Kidney impairment: no dose change is needed.

Abiraterone overdose

▾

Experience with overdose is limited, and there is no specific antidote. If too much is taken, abiraterone should be stopped. Care is supportive, including monitoring for heart rhythm problems and heart failure and checking liver function.

What Abiraterone does in the body

▾

Abiraterone lowers testosterone and other androgens. Because it affects hormones, it can raise mineralocorticoid levels, causing blood pressure and potassium changes. In a small study, no large change in the heart's QTc interval was seen, though a small increase could not be ruled out. PSA changes may occur but do not reliably show benefit in an individual patient.

How your body processes Abiraterone

▾

Abiraterone acetate is converted in the body to active abiraterone, which peaks in about 2 hours. Food sharply raises absorption, which is why the fasting directions matter for some products. The average half-life is about 12 hours. It is cleared mostly in the feces (about 88%) and a small amount in urine (about 5%). Moderate or severe liver impairment raises abiraterone levels substantially.

How to store Abiraterone

▾

Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) . Keep out of reach of children.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

181

Supplements & herbs that interact with Abiraterone

181 supplements and herbal products have documented interactions with Abiraterone in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 137
  • Minor · 38
ACTIVATED CHARCOAL Major BEER Major GRAPEFRUIT Major SIBERIAN COCKLEBUR Major ST. JOHN'S WORT Major WINE Major ACACIA RIGIDULA Moderate ADRAFINIL Moderate +173 more
Every supplement checked against Abiraterone — ranked by severity The full interaction hub: 6 major · 137 moderate · 38 minor · every one linked to its full report. Check Abiraterone against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Abiraterone: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Abiraterone — the kind of thing our pharmacy team would talk through with you at the counter.

What is abiraterone for?

▾
It treats prostate cancer that has spread. Abiraterone acetate tablets, Abirtega and Zytiga are used for metastatic castration-resistant and metastatic high-risk castration-sensitive prostate cancer, with prednisone. Yonsa is used for the castration-resistant type, with methylprednisolone.

How should I take it, and does food matter?

▾
Take it once a day and swallow the tablets whole with water. With abiraterone acetate tablets, Abirtega or Zytiga, don't eat for 2 hours before or 1 hour after your dose, because food greatly raises how much drug you absorb. Yonsa can be taken with or without food. Check which product you have.

Why do I need to take a steroid with it?

▾
Abiraterone can cause a hormone imbalance, leading to high blood pressure, low potassium and fluid retention. The steroid is part of your treatment. Don't skip it or stop suddenly, because that can cause adrenal insufficiency, which can be serious.

What side effects are common, and which should I call about?

▾
Common ones are tiredness, joint pain, swelling, high blood pressure, nausea, diarrhea and hot flushes. Call your doctor about yellow skin or eyes, dark urine, severe weakness or dizziness, a racing or irregular heartbeat, shortness of breath, or new swelling. Your blood pressure, potassium and liver tests will be checked regularly.

Are there medicines I should watch out for?

▾
Yes. Tell me about everything you take. Strong CYP3A4 inducers like rifampin can weaken abiraterone. It can raise levels of certain drugs such as thioridazine. If you take pioglitazone or repaglinide for diabetes, your blood sugar needs watching. Radium Ra 223 together with it is not recommended.

Is it safe around pregnancy?

▾
It can harm an unborn baby. If you're a man with a partner who could become pregnant, use effective contraception during treatment and for 3 weeks after your last dose. Women who are or may be pregnant shouldn't handle the tablets.

Is Abiraterone available over the counter?

▾
No. Abiraterone is a prescription medicine: every Abiraterone product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Abiraterone first available?

▾
The earliest FDA record we hold for Abiraterone is from 2010: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Abiraterone was first used.

Who makes Abiraterone?

▾
23 companies currently list Abiraterone products in the FDA's NDC Directory, including Amneal Pharmaceuticals NY LLC, Dr. Reddys Laboratories Inc, Northstar Rx Llc. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Abiraterone on HelloPharmacist

📊Abiraterone supplement interactions181 checked — ranked by severity 🌿Drug & Supplement CheckerAbiraterone vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Abiraterone NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Abiraterone Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Abiraterone forms and strengths (how it comes)

Abiraterone is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Abirtega Yonsa Zytiga
How this form is used
What it may be used for
  • Abiraterone acetate tablets, Abirtega and Zytiga are used with prednisone for metastatic CRPC and metastatic high-risk CSPC.
  • Yonsa is used with methylprednisolone for metastatic CRPC.
Important instructions
  • Abiraterone acetate tablets, Abirtega and Zytiga are taken once daily on an empty stomach: no food 2 hours before or 1 hour after.
  • Yonsa is taken once daily with or without food. Its dosing and food effects may differ from other abiraterone products, so avoid mixing up products.
  • For all of these tablets, swallow whole with water. Do not crush or chew.
Available strengths 3 strengths
125 mg 250 mg 500 mg
93 FDA-listed product records ⓘ

Abiraterone on the U.S. market: products, makers and brands

How Abiraterone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

23 companies list 43 Abiraterone product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2010. Brand names on the directory include Zytiga, Yonsa, Abirtega; the rest are generics.

1
Dose forms ⓘ
23
Labelers (makers, repackagers, distributors)
5
Brand names
43
FDA-listed product records ⓘ
2010
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (30) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Amneal Pharmaceuticals NY LLC9%
Dr. Reddys Laboratories Inc7%
Northstar Rx Llc7%
Novadoz Pharmaceuticals LLC7%
Apotex Corp.5%
AvKARE5%
Other makers60%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Abiraterone is used (Medicaid data)

A general measure of how commonly Abiraterone is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Abiraterone is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

14,531
Medicaid prescriptions filled (Q1–Q4 2025)
$14.3M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Abiraterone prescribed? Of the 1,601 medications we measure, Abiraterone ranks #861 by Medicaid prescriptions — more than 46% of them.

Where Abiraterone ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #861 of 1,601
#856 Romosozumab-aqqg Injec... 14,773 Rx #857 Bismuth, Metronidazole... 14,740 Rx #858 Etoposide 14,672 Rx #859 Desmopressin Nasal 14,664 Rx #860 Hydrocortisone Injecti... 14,630 Rx #861 Abiraterone 14,531 Rx #862 Etoposide Injection 14,504 Rx #863 Azacitidine 14,325 Rx #864 Teriparatide Injection 14,225 Rx #865 Etelcalcetide Injectio... 14,185 Rx #866 Azacitidine Injection 14,177 Rx

Utilization by Abiraterone product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 250 mg oral tablet is the most-dispensed Abiraterone product — about 71% of these Medicaid prescriptions.

abiraterone acetate 250 MG Oral Tablet Most dispensed

10,341 Medicaid prescriptions (Q1–Q4 2025) 71% of Abiraterone prescriptions shown $6M gross reimbursement (before rebates) ≈ $585 per prescription (gross)

Summed across the 14 of 42 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1100075

abiraterone acetate 500 MG Oral Tablet

4,190 Medicaid prescriptions (Q1–Q4 2025) 29% of Abiraterone prescriptions shown $8.3M gross reimbursement (before rebates) ≈ $1,975 per prescription (gross)

Summed across the 11 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1918042

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Abiraterone, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 25 of 64 listed Abiraterone NDCs with Medicaid activity.

Compare Abiraterone products

A representative set of FDA-listed product records for Abiraterone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 43 of 43 products — FDA National Drug Code Directory. See every product, package size and price: browse all 43 Abiraterone NDCs →

Abiraterone recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Abiraterone recalls since July 2021.

✅No Abiraterone recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Abiraterone RxCUI 1100072 1 dose form · 3 strengths

Look up RxCUI 1100072 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Abiraterone costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet · Oral 250 mg $0.774 per tablet NDC details & price history
Tablet, Film Coated · Oral 500 mg $2.59 per tablet NDC details & price history
Tablet, Film Coated · Oral 250 mg $0.774 per tablet NDC details & price history
Tablet · Oral; Oral 250 mg $0.774 per tablet NDC details & price history
Tablet · Oral, Oral 250 mg $0.774 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Abiraterone brand names

Abiraterone is sold under 3 brand names in the FDA directory — Zytiga, Yonsa, Abirtega. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Zytiga Yonsa Abirtega

Who makes Abiraterone: manufacturers and labelers

23 companies list Abiraterone products with the FDA. By number of product records, the largest are Amneal Pharmaceuticals NY LLC, Dr. Reddys Laboratories Inc, Northstar Rx Llc. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Amneal Pharmaceuticals NY LLC 4 Dr. Reddys Laboratories Inc 3 Northstar Rx Llc 3 Novadoz Pharmaceuticals LLC 3 Apotex Corp. 2 AvKARE 2 BluePoint Laboratories 2 CivicaScript, LLC 2 Florida Pharmaceutical Products, LLC 2 Glenmark Pharmaceuticals Inc., USA 2 Golden State Medical Supply, Inc. 2 Janssen Biotech, Inc. 2 Mylan Pharmaceuticals Inc. 2 Novugen Pharma (USA) LLC 2 Quallent Pharmaceuticals Health LLC 2 American Health Packaging 1 AvPAK 1 Bryant Ranch Prepack 1 Hikma Pharmaceuticals USA Inc. 1 Major Pharmaceuticals 1 PD-Rx Pharmaceuticals, Inc. 1 Rising Pharma Holdings, Inc. 1 Sun Pharmaceutical Industries, Inc. 1

Abiraterone drug class (RxNorm)

Abiraterone belongs to the Cytochrome P450 17A1 Inhibitor class.

Pharmacologic class Cytochrome P450 17A1 Inhibitor
Drug family (ATC) Other hormone antagonists and related agents, Poly (ADP-ribose) polymerase (PARP) inhibitors
How it works Cytochrome P450 2D6 Inhibitors, Cytochrome P450 17A1 Inhibitors, Cytochrome P450 2C8 Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Abiraterone page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Feb 26, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Abiraterone.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Abiraterone after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
31
Finished products in the current FDA directory
43
Companies listing them (makers, repackagers, distributors)
23
FDA labeler codes behind them ⓘ
26
Linked representative label ⓘ
American Health Packaging
Linked label effective
Feb 26, 2025
Composite sections available
23
Linked SPL Set ID
b36bff33-595e-4827-9a73-85c6954c314c
Linked SPL Document ID
2f0ff61e-95d0-1f19-e063-6294a90a2e7b
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. American Health Packaging is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →